Bryan R. Dunlap

Pillsbury Winthrop Shaw Pittman (New York)

Bryan R. Dunlap is a lawyer at Pillsbury Winthrop in their New York office.

Linked authors

Pillsbury Winthrop Shaw Pittman (Beijing)
Pillsbury Winthrop Shaw Pittman (Beijing)

Articles

287 Bulletin

Bryan R. Dunlap, Richard Liebeskind, William DeVinney The US FTC employs an uncommon remedy to resolve the anticompetitive concerns of a merger-to-monopoly by requiring the merged firm to license a generic form of its breakthrough cancer pain drug to a third party (Cephalon / CIMA)

160

In two recent decisions involving pharmaceutical mergers – Cephalon/Cima, in August 2004, and Genzyme/Novazyme, in January 2004, a divided Federal Trade Commission was accused by dissenting Commissioners of breaking with precedent and allowing acquisitions involving innovator pharmaceuticals (...)

Bryan R. Dunlap, Richard Liebeskind, William DeVinney The US FTC requires divestiture of three brand drugs in order to grant approval to a merger between two pharmaceutical companies (Sanofi-Synthelabo / Aventis)

127

In two recent decisions involving pharmaceutical mergers – Cephalon/Cima, in August 2004, and Genzyme/Novazyme, in January 2004, a divided Federal Trade Commission was accused by dissenting Commissioners of breaking with precedent and allowing acquisitions involving innovator pharmaceuticals (...)

Send a message